H.C. Wainwright lowered the firm’s price target on HeartBeam (BEAT) to $2.50 from $5.50 and keeps a Buy rating on the shares post the Q1 report. The firm believes the company’s revenue scaling may take longer time than initially expected. H.C. Wainwright cites HeartBeam’s relatively slower sales ramp-up compared to its previous expectations for the target cut.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BEAT:
- HeartBeam price target lowered to $5 from $8 at Benchmark
- HeartBeam Earnings Call: Funding Extends Runway, Trials Advance
- HeartBeam (NASDAQ: BEAT) Advances Commercial Launch, Reports First-Quarter 2026 Results
- HeartBeam reports Q1 EPS (12c) vs. (18c) last year
- HeartBeam (NASDAQ: BEAT) Launches Pilot Study for On-Demand 12-Lead ECG Patch in Coronary Artery Disease Patients